1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Sintilimab: new trials by email Literature Review of Sintilimab trials Research Report on Sintilimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC Neoadjuvant therapy 1 - Sintilimab, Lung Cancer | Phase 2 | Active not recruiting | Tang-Du Hospital | 45 | 2021-03-01 | 2024-10-18 |
Lung Neoplasms (1)
Lung Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Drug Therapy (1) · anlotinib (1) · sintilimab (1)
Tang-Du Hospital (1)
China (1)